AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04250077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Reinforcement And Family Training (CRAFT)
Description: Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior.
Study NCT04250077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: We The Village Peer Community Forum
Description: An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
Study NCT00315757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mapatumumab
Description: 10 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
Study NCT00315757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mapatumumab
Description: 20 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
Study NCT00315757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: 1.3 mg/m\^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
Study NCT00315757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m\^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
Study NCT04148144 — intervention group
Intervention type: OTHER
Intervention: No intervention included
Description: No intervention included
Study NCT03452748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FTIR spectroscopy
Description: FTIR spectroscopy examines collagen fibers in the excised membranes
Study NCT02150902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wide area circumferential catheter ablation
Description: All subjects in the control arm of the trial will undergo wide area circumferential catheter ablation (WACA; lesions delivered 1-2 cm away from the pulmonary vein ostium) around all four pulmonary veins to the endpoint of electrical isolation (demonstrated by entry and exit block using differential pacing). Catheter ablation will be performed using contact force (CF) and electroanatomical mapping system guidance (average CF >10g, FTI > 500 g-sec and minimum ablation duration >10 sec). Dormant pulmonary vein conduction will be tested using adenosine, after completion of the lesion set, and additional lesions will be delivered to eliminate dormant PV conduction.
Study NCT02150902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Augmented- wide area circumferential ablation procedure
Description: Subjects in this group will have WACA performed as described for WACA. Following completion of the WACA procedure a second set of circumferential ablation lesions will be delivered around the first set of ablation lesions. The ablation catheter tip will be positioned at each of the ablation lesions along the first WACA line and then moved away (from the PV ostia) until healthy, non ablated tissue is recorded from the catheter tip. Energy will be delivered using CF and FTI data as described previously. Once the first WACA ablation line has been completely duplicated the procedure will be deemed complete. In case PV isolation is not achieved after the first WACA lesion set repeat electrophysiologic testing will be performed to determine whether the augmented-WACA procedure was successful in achieving PV isolation.
Study NCT04957732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irrisept Delivery System
Description: Irrisept is a manual, self-contained irrigation device capable of producing 7-8 psi of pressure for effective wound cleansing and irrigation. Irrisept contents include the Chlorhexidine Gluconate (CHG) solution, a 450 mL bottle, and Irriprobe applicator or an abscess irrigation tip. The bottle design allows users to control the pressure of the solution through manual bottle compression. The device had an option for use with an Irriprobe applicator or an abscess irrigation tip. Irrisept was used at the initial visit and at each subsequent 48-hour visit interval (up to 96 hours) until abscess healing.
Study NCT01932086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
Study NCT01466296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chaotic Perturbation
Description: Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the random shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will impose perturbations in the range tolerated by the subject. The therapist will make a written report of each session.
Study NCT01466296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dummy not active shoes
Description: Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the dummy shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will not impose perturbations. The therapist will make a written report of each session.
Study NCT01466296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will exercise basic stretching and muscle strengthening, then walk on the treadmill. A physiotherapist according the subject's rate of improvement will determine the increase in treadmill velocity and slope. The therapist will make a written report after each session.
Study NCT01932086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose solution
Description: All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.
Study NCT01932086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose solution
Description: All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.
Study NCT02591927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-Insulin-Potassium
Description: Rackley's GIK formula by continuous I.V. infusion at 1.5 ml/Kg/hour for 12 hours (about 100 ml/hour for a 70 kg patient).
Study NCT02378402 — intervention group
Intervention type: OTHER
Intervention: Proton (1H-) magnetic resonance (MR) spectroscopy
Description: PRESS localized 1D MRS sequence was used on a 3-T MR system. The lipid resonances will be analyzed using the LC-Model algorithm, and a Cramer-Rao lower bound (CRLB) threshold of 50% was used as quality control. Resonances of fatty acid (FA, lipid resonances δ 0.9, 1.3 and 1.6 ppm) and polyunsaturated fatty acid (PUFA, lipid resonance δ 2.1 and 2.3, 2.8, 5.3 ppm) will be evaluated on MRS, with ratios normalized with total TG value.
Study NCT02444234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid PO
Description: Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.
Study NCT02591927 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose 5%
Description: Glucose 5% (Placebo) by continuous I.V. infusion at 1.5ml/kg/hour for 12 hours (about 100 ml/hour for 70 Kg patient)
Study NCT04366401 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Dietary Advice
Description: The education content in the control group will be centered on the acquisition of knowledge about:~* - Underlying mental pathology, lifestyles and associated comorbidities~* - Immediate principles: Carbohydrates, lipids, proteins, fiber, vitamins, and minerals; energy needs; consumption requirements.~* - Water requirements.~* - Foodstuffs.~* - Culinary techniques: conservation of properties of the diet.~* - Feeding in particular situations.
Study NCT04366401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prebiotic/Probiotic Dietary Modulation
Description: The education content in the intervention group will be based on general principles of conventional dietary advice in an intensified manner, centered on the acquisition of specific knowledge about:~* - Underlying mental pathology, lifestyles and associated comorbidities~* - Immediate principles: Carbohydrates, lipids, proteins, fiber, vitamins, and minerals; energy needs; consumption requirements.~* - Water requirements.~* - Foodstuffs.~* - Description and justification of prescribed prebiotic and probiotic diet.~* - Culinary techniques: conservation of properties of the prebiotic and probiotic diet.~* - Optimal distribution and interchange of foods with high prebiotic and probiotic content.~* - Feeding in particular situations.
Study NCT02466880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: A diabetes self-management and education program delivered via telemedicine
Study NCT00870103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Description: 1 drop every 6 hours into the study eye
Study NCT02585570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Patients is received phenylephrine 1.0 mcg/kg/min or 0.5 mcg/kg/min for 5 minutes before being placed in the beach chair position.
Study NCT04352153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
Study NCT04352153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uralyt-U
Description: Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
Study NCT03613272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subxiphoid approach extended thymectomy by VATS
Description: Extended thymectomy performed through the subxiphoid-right VATS approach with double elevation of the sternum
Study NCT03613272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostal approach extended thymectomy by VATS
Description: Extended thymectomy performed through the traditional intercostal VATS approach
Study NCT02444234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid IV
Description: Participants will be randomized to receive tedizolid IV 200mg once daily for 3 days and crossed over to PO after a 1 week washout.
Study NCT01873547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell therapy
Description: Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
Study NCT01873547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Description: Patients only receive rehabilitation of limb function.
Study NCT06393686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga
Description: The yoga intervention will be implemented every two weeks, with each session lasting 45 minutes and implemented for 10 weeks. Sessions will always be led by the same certified yoga instructor. Each session will include a variety of different yoga poses, as well as breathing techniques and deep relaxation methods.
Study NCT02882152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femoral nerve blockade
Description: femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve at the end of the surgery
Study NCT02882152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Intrathecal morphine injection
Study NCT02133170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Description: The MBCT program is conducted in HULP (BRV and CBP), which also train therapists from Vitoria, in order to homogenize the intervention. Random sessions are video or audio recorded to be discussed and analyzed by the treatment team. The manualized MBCT therapy consists of 8 weekly sessions of 90 minutes and is applied in groups of approximately 10-15 patients. At least two programs in H. La Paz and two in the hospital de Santiago (Vitoria) will be provided.
Study NCT02133170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation program will be held in groups of 10 to 15 patients in 90-minute weekly sessions led by two therapists also outside the research team. The specific program of 8 sessions is focused addressing disease awareness, adherence to treatment and early detection of prodromal symptoms. Homework will also be included. The program is based on the Psychoeducation Manual for Bipolar Disorder . F.Colom , E.Vieta . Ars Medica, 2004. Attendance at least 80 % of the sessions of both interventions will be required to be considered complete.
Study NCT02133170 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard treatment
Description: Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
Study NCT02248688 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BeadBlock 300 - 500 Micron
Description: Beadblock will be used intraarterially to occlude the left gastric artery and its branches. The left gastric artery supplies the fundus of the stomach, where it is known that the hormone Ghrelin (one of the hormones responsible for appetite) is produced.
Study NCT02248688 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Left Gastric Artery Embolization
Study NCT03860935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acoramidis
Description: TTR stabilizer administered orally twice daily (BID)
Study NCT03860935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Non-active control administered orally twice daily (BID)
Study NCT01463007 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation
Description: Accuboost APBI 34.0 Gy in 10 fractions
Study NCT01463007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended Follow up
Description: This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
Study NCT03190044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PACR
Description: Daily assumption of PACR for a 3-month period
Study NCT03190044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily assumption of placebo
Study NCT00634738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic Compression (thumb Pressure)
Description: Pressure, one thumb on the other, applied on the trigger points
Study NCT04321785 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule (mannitol)
Study NCT04321785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: caffeine capsule (80 mg of caffeine plus mannitol)
Study NCT00477958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Questionnaire administered prior to chemotherapy and within 30 days of completion of chemotherapy.
Study NCT00477958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive assessment
Description: Cognitive assessment to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
Study NCT00477958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Psychosocial assessment and care to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
Study NCT02706223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Led
Description: Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects
Study NCT02706223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse led
Description: Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses
Study NCT02186301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib Mono-Therapy
Description: Rociletinib will be administered twice daily
Study NCT02186301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib Mono-Therapy
Description: Erlotinib will be administered once a day
Study NCT03879343 — intervention group
Intervention type: OTHER
Intervention: Known diagnosis of attention deficit / hyperactivity disorder
Description: Clinical group includes subjects with clinical diagnosis of attention deficit / hyperactivity disorder
Study NCT02528721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Mode BreathID Hp System
Description: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device
Study NCT04396184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic acid photodynamic therapy
Description: Aminolevulinic acid photodynamic therapy
Study NCT04396184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid photodynamic therapy
Description: Aminolevulinic acid photodynamic therapy
Study NCT02883699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard endurance training
Description: Continuous vigorous training 2 x per week on a cycle ergometer
Study NCT00482222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT01343823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ecallantide 60 mg
Description: Administered as two 3 mL SC injections, each containing 30 mg ecallantide
Study NCT01343823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ecallantide 30 mg
Description: Administered as one 3 mL SC injection containing 30 mg ecallantide
Study NCT01343823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ecallantide 10 mg
Description: Administered as one 3 mL SC injection containing 10 mg ecallantide.
Study NCT01343823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered as two SC 3 mL injections
Study NCT01343823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo match for 30 mg ecallantide arm
Description: One 3 mL SC injection of matching placebo given to subjects randomized to the 30 mg ecallantide arm.
Study NCT01343823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo match for 10 mg ecallantide arm
Description: One 3 mL SC injection of matching placebo given to subjects randomized to the 10 mg ecallantide arm.
Study NCT02883699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Polarized endurance training
Description: Continuous moderate training 1 x per week and aerobic high intensity interval training (HIIT) 1 x per week on the cycle ergometer
Study NCT02883699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard resistance training
Description: Machine based hypertrophy training 2 x per week